Comparative Pharmacology
Head-to-head clinical analysis: LUDIOMIL versus MAPROTILINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LUDIOMIL versus MAPROTILINE HYDROCHLORIDE.
LUDIOMIL vs MAPROTILINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tricyclic antidepressant; inhibits reuptake of norepinephrine and serotonin at presynaptic terminals, increasing synaptic concentrations of these neurotransmitters.
Maprotiline is a tetracyclic antidepressant that inhibits the reuptake of norepinephrine and, to a lesser extent, serotonin, thereby increasing their synaptic concentrations; it also has mild anticholinergic activity and blocks histamine H1 receptors.
Oral, 75-150 mg daily in divided doses (or as a single dose at bedtime); may increase to 225 mg daily. Maximum: 300 mg daily.
75-150 mg orally once daily; initial dose 25-75 mg/day, increase gradually. Maximum 225 mg/day.
None Documented
None Documented
51 hours (range 36–68 h) in adults; requires dose adjustment in hepatic impairment.
Terminal elimination half-life approximately 27-58 hours (mean 43 hours); may be prolonged in elderly or hepatic impairment; allows once-daily dosing at steady state within 7-14 days
Primarily renal (≥60% as metabolites, ~2% unchanged); biliary/fecal excretion accounts for ~30%.
Primarily renal (70-80% as metabolites, <5% unchanged); biliary/fecal (20-30%)
Category C
Category C
Tetracyclic Antidepressant
Tetracyclic Antidepressant